EU and US could reach trade deal this weekend - Reuters
TD Cowen reiterated its Buy rating and $168.00 price target on Globe Life (NYSE:GL) Wednesday, maintaining the insurer as its top pick in the U.S. life insurance sector. According to InvestingPro data, analyst targets for the stock range from $118 to $188, with the company receiving a GREAT financial health score.
The research firm cited Globe Life’s "attractive business model" that produces strong and consistent growth despite recent headwinds. The company has demonstrated this with a 5.41% revenue growth over the last twelve months. TD Cowen acknowledged that margin pressure in the Health segment and soft first-quarter 2025 Life sales have affected investor sentiment.
The company continues to target the "large/underserved U.S. lower-middle to middle-income market" with exclusive distribution channels that face limited competition, according to TD Cowen’s analysis. Globe Life has reaffirmed its fiscal year 2025 earnings per share guidance despite these challenges. Notably, the company has maintained dividend payments for 55 consecutive years, demonstrating long-term financial stability. For more detailed insights and exclusive financial metrics, check out the comprehensive Pro Research Report available on InvestingPro.
TD Cowen characterized the ongoing regulatory inquiry as "limited in scope" and suggested it could resolve in the second half of 2025. The firm noted Globe Life has "relatively modest balance sheet risk and market sensitivity."
The stock currently trades at approximately 8 times expected 2026 earnings, significantly below its 12.1 times next-twelve-months average from 2018 until April 2024, when a short seller report was published. TD Cowen sees "significant upside potential" as regulatory concerns diminish.
In other recent news, Globe Life reported its first-quarter earnings for 2025, revealing an earnings per share (EPS) of $3.07, which missed the forecasted $3.24. However, the company’s revenue exceeded expectations, reaching $1.48 billion against a forecast of $1.45 billion. Despite the earnings miss, life insurance premium revenue grew by 3% to $830 million, and health insurance premium revenue increased by 8% to $370 million. Evercore ISI adjusted its price target for Globe Life, reducing it from $143.00 to $141.00, while maintaining an Outperform rating. The adjustment followed weaker-than-expected performance in the health insurance sector, with an 8% decrease in health insurance earnings primarily due to higher claims in Medicare supplement insurance. Evercore ISI analysts have slightly increased their full-year 2025 earnings projections for Globe Life, although they decreased their second-quarter earnings forecast by 5-6% and by roughly 2% for 2026. The company anticipates health earnings will recover, with margins expected to be between 24-26% for the full year 2025. Additionally, Globe Life is expected to announce plans regarding its Bermuda captive reinsurance vehicle with its second-quarter results, which could potentially accelerate share repurchases in 2026 and 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.